-+ 0.00%
-+ 0.00%
-+ 0.00%

Curevac And GSK Have Agreed To Resolve And Dismiss All Pending Patent Litigation In The US With BioNTech And Pfizer, Related To mRNA-Based COVID-19 Vaccines, CureVac and GSK Will Receive $740M And Single-Digit Royalties

Benzinga·08/08/2025 09:42:31
Listen to the news
  • Under the terms of the agreements, CureVac and GSK will receive in aggregate a payment of $740 million as well as single-digit royalties on sales of COVID-19 vaccines in the United States going forward. Additionally, CureVac will receive $50 million from GSK for monetizing a portion of U.S. product royalties due under its existing license agreement announced on July 3, 2024.
  • Furthermore, as part of the settlement agreements, CureVac will grant BioNTech and Pfizer a non-exclusive license to manufacture, use, import into the U.S. and sell mRNA-based COVID-19 and/or influenza products. Such non-exclusive license will be expanded into a worldwide license upon the closing of BioNTech's acquisition of CureVac.
  • Subject to regulatory approval, BioNTech's acquisition of CureVac as announced on June 12, 2025 will be implemented as planned and its terms will remain unaffected.